Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial by Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer, Gabor Kovacs, Marco Herling, Eugen Tausch, Karl-Anton Kreuzer, Barbara Eichhorst, Sebastian Böttcher, John F. Seymour, Paolo Ghia, Paula Marlton, Michael Kneba, Clemens-Martin Wendtner, Hartmut Döhner, Stephan Stilgenbauer, and Michael Hallek Blood Volume 127(2):208-215 January 14, 2016 ©2016 by American Society of Hematology PFS and OS in both treatment arms. Kirsten Fischer et al. Blood 2016;127:208-215 ©2016 by American Society of Hematology PFS and OS in both treatment arms and IGHV MUT/UNM patients. Kirsten Fischer et al. Blood 2016;127:208-215 ©2016 by American Society of Hematology OS in genetic subgroups of IGHV MUT FCR patients (N = 107). Kirsten Fischer et al. Blood 2016;127:208-215 ©2016 by American Society of Hematology
© Copyright 2024 ExpyDoc